#ALMR
🚨 $ALMR
Initial Filing Analysis Error
SEC Filing: ALMR
Click to view the official SEC document.
www.sec.gov
November 19, 2026 at 10:08 PM
🚨 $ALMR
Chen Shiping (Chief Operating Officer) reported special transactions (Non-P/S).
SEC Filing: ALMR
Click to view the official SEC document.
www.sec.gov
November 19, 2026 at 10:10 PM
New study raises hopes for blood test to detect CTE #$ALMR firstwordhealthtech.com/story/8473340
Loading...
firstwordhealthtech.com
November 20, 2026 at 11:19 PM
#ALMR JAMA Study Using Alamar Biosciences’ NULISA Assay Links Blood eMTBR-tau to Tau tangle Burden in Former Football Players w…

https://www.stocktitan.net/news/ALMR/jama-study-using-alamar-biosciences-nulisa-assay-links-blood-e-mtbr-qme2umpj1bts.html?utm_source=stocktitan-bluesky&utm_medium=social
JAMA Study Using Alamar Biosciences’ NULISA Assay Links Blood eMTBR-tau to Tau tangle Burden in Former Football Players with Advanced CTE
Alamar Biosciences (ALMR) announced a JAMA study that used its NULISA blood test and linked higher eMTBR-tau levels to more tau tangles in the brain.The study included 21 former American football players who gave blood during life and later donated their brains. Eighteen had chronic traumatic encephalopathy (CTE), including 16 with high-stage disease. Blood levels of eMTBR-tau, a protein fragment, were higher in players with high-stage CTE than in those with low-stage or no CTE.The test is not diagnostic or available for clinical use. CTE can still be confirmed only by examining the brain after death, and the researchers said the findings need validation in larger, more diverse groups.
www.stocktitan.net
November 20, 2026 at 1:30 PM
$OKTA-1 $VIXY-1 $VWO-1 $EXEL-1 $RIOT-1 $MYGN-1 $SPDW-1 $UPRO-1 $RIG-1 $OSCR-1 $SNAP-1 $COMP-1 $SSPC-1 $ELPW-1 $FOSL-1 $ALMR-1 $QMCO-1 $LITX-1 $CALM-1 $MSTX-1 $VSNT-1 $UBS-1 $ENPH-1 $CNQ-1 $LOFF-1 $VKTX-1 $EFA-1 $TSLQ-1 $CIEN-1 $VMI-1
November 5, 2026 at 9:46 PM
🚨 $ALMR
Qiming Corporate GP VI, Ltd. () sold 187,636 shares at an average price of $30.2523 per common share. (Date: 2026-11-02)
SEC Filing: ALMR
Click to view the official SEC document.
www.sec.gov
November 3, 2026 at 9:41 PM
#ALMR UPDATE -- Alamar Biosciences and Nightingale Health to Lead UK Biobank 80,000-Sample Neurodegenerative Disease Study

https://www.stocktitan.net/news/ALMR/update-alamar-biosciences-and-nightingale-health-to-lead-uk-biobank-ijpwxzlsj1jr.html?utm_source=stocktitan-bluesky&utm_medium=social
UPDATE -- Alamar Biosciences and Nightingale Health to Lead UK Biobank 80,000-Sample Neurodegenerative Disease Study
Alamar Biosciences (ALMR) and Nightingale Health launched a UK Biobank study to measure neurodegenerative disease biomarkers in 80,000 blood samples.The UKB-PRISM study will measure hundreds of circulating proteins in Nightingale’s laboratories using Alamar’s NULISA platform. It focuses on early molecular indicators associated with Parkinson’s disease, Alzheimer’s disease and other neurodegenerative conditions, including rare dementias. The Michael J. Fox Foundation, Alzheimer’s Research UK and LifeArc are funding the study. Completion is expected by the end of 2027, with the protein measurements to complement UK Biobank’s imaging, genetic, metabolomic and lifestyle data.
www.stocktitan.net
November 3, 2026 at 12:05 AM
www.stocktitan.net
November 2, 2026 at 1:00 PM
🚨 $ALMR
Qiming Corporate GP VI, Ltd. () sold 185,731 shares at an average price of $32.1373 per common share. (Date: 2026-10-28)
SEC Filing: ALMR
Click to view the official SEC document.
www.sec.gov
October 29, 2026 at 8:12 PM
🚨 $ALMR
Qiming Corporate GP VI, Ltd. () sold 280,458 shares at an average price of $30.5563 per common share. (Date: 2026-10-26)
SEC Filing: ALMR
Click to view the official SEC document.
www.sec.gov
October 27, 2026 at 8:15 PM
🕵️ Monday insiders: sells $32.93M vs buys $9.52M — 3.5x. #$TRV EVP sells $14.04M (65% of his stake) near highs after a Q3 beat. #$ALMR 10% owner sells $10.25M. #$DOLE 10% owner buys $8.55M near lows. #$LIND founder sells $8.64M. #$RAPP director buys $0.97M here. [NOT FINANCIAL ADVICE, DYOR!]
October 26, 2026 at 3:29 PM
🚨 $ALMR
Qiming Corporate GP VI, Ltd. () sold 342,626 shares at an average price of $29.9250 per common share. (Date: 2026-10-22)
SEC Filing: ALMR
Click to view the official SEC document.
www.sec.gov
October 23, 2026 at 11:35 PM
🚨 $ALMR
Qiming Corporate GP VI, Ltd. () sold 217,512 shares at an average price of $27.3547 per common share. (Date: 2026-10-20)
SEC Filing: ALMR
Click to view the official SEC document.
www.sec.gov
October 21, 2026 at 11:15 PM
🚨 $ALMR
Qiming Venture Partners VI, L.P., a Affiliate, filed a notice of intent to sell 1,558,858 shares of common stock, valued at approximately $36,664,000.00, on 10/14/2026.
SEC Filing: ALMR
Click to view the official SEC document.
www.sec.gov
October 15, 2026 at 12:21 AM
🚨 $ALMR
Qiming Venture Partners VIII Investments, LLC, a Affiliate, filed a notice of intent to sell 363,729 shares of common stock, valued at approximately $8,555,000.00, on 10/14/2026.
SEC Filing: ALMR
Click to view the official SEC document.
www.sec.gov
October 15, 2026 at 12:23 AM
🚨 $ALMR
Qiming Managing Directors Fund VI, L.P., a Affiliate, filed a notice of intent to sell 41,945 shares of common stock, valued at approximately $987,000.00, on 10/14/2026.
SEC Filing: ALMR
Click to view the official SEC document.
www.sec.gov
October 15, 2026 at 12:15 AM
🚨 $ALMR
Qiming Venture Partners VIII-HC, L.P., a Affiliate, filed a notice of intent to sell 435,468 shares of common stock, valued at approximately $10,242,000.00, on 10/14/2026.
SEC Filing: ALMR
Click to view the official SEC document.
www.sec.gov
October 15, 2026 at 12:33 AM
#ALMR Lancet Neurology Study Using Alamar Biosciences’ Technology Reveals Divergent Biological Responses to Alzheimer’s Treatment

https://www.stocktitan.net/news/ALMR/lancet-neurology-study-using-alamar-biosciences-technology-reveals-jd0m1htdiwxk.html?utm_source=stocktitan-bluesky&utm_medium=social
Lancet Neurology Study Using Alamar Biosciences’ Technology Reveals Divergent Biological Responses to Alzheimer’s Treatment
Alamar Biosciences (ALMR) announced a Lancet Neurology study using its NULISAseq CNS 120 panel to examine responses to lecanemab treatment.Researchers profiled 2,385 plasma samples from 1,967 participants, including 197 patients treated with lecanemab and untreated comparison groups. Among treated patients, 34 of 130 measured biomarkers changed significantly with the number of infusions, and the changes did not all move in the same direction. Proteins associated with amyloid clearance were largely different from those associated with subsequent cognitive decline. Brain-derived forms of tau accounted for four of the top five proteins that most strongly distinguished treated patients from controls both before treatment and at the last infusion stage.
www.stocktitan.net
September 24, 2026 at 10:51 PM